Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Analysis is performed on the observed clinical picture of vinyl-chloride disease in 12 persons, developed at concentrations of toxic substance about MAC after exposure from 5 to 34 years. After enlarged clinical test on individual organs and systems the authors establish that the most frequent result of chronic poisoning with vinyl-chloride is the combination of peripheral neurovegetative symptoms with toxic hepatitis on the background of neurosis-similar (astheno-vegetative) manifestations. In the cases, observed by the authors, the poisoning takes a light course affecting the neurovegetative structures and prevailing of the vegetovasal forms of polyneuropathy ending with Raynaud-similar syndrome, or affecting the distal parts of the peripheral nerves with early electromyographic find. The Raynaud-similar syndrome and the bone changes ad specificity to the clinical picture, but are not constant manifestation of poisoning and can be developed at more continuous occupational exposure. The authors propose a discussion on the legality of the appelation vinyl-chloride disease in the cases, when not all classical clinic symptoms are present.
 ...
PMID:[A clinical observation of vinyl chloride-induced disease]. 136 41

The frequencies of hepatitis A and hepatitis B markers were determined in 291 members of the staff and 714 patients of a psychiatric institution for adults. 71.8% of the patients suffered from psychosis, 17.7% from neurosis, and 10.6% from oligophrenia. 84.4% of the patients and 69.2% of the staff were anti-HAV-positive. - 26.8% of the patients and 19.9% of the staff showed at least one HBV marker. The frequency of anti-HBc increased with age but not with hospitalization. Anti-HBc-positive persons did not show transaminase abnormalities more often as reported previously. - 2.6% of the patients were presumable Non-A, Non-B hepatitis cases after excluding IgM-anti-HAV, IgM-anti-CMV or -EBV and possible toxic effects. The rate of presumable Non-A, Non-B hepatitis equaled the frequency of HBsAg-positive persons.
 ...
PMID:Hepatitis A and B markers and presumable non-A, non-B hepatitis in a psychiatric institution. 628 59

Hepatitis A and B markers were determined in 714 patients and in 291 members of the staff of a psychiatric institution for adults. The leading diagnosis were psychosis (71.8%), neurosis (17.7%), and oligophrenia (10.6%). Anti-HAV was found in 84.4% of the patients and in 69.2% of the staff. 26.8% of the patients and 19.9% of the staff had at least one HBV marker. The frequency of HBV markers correlated with the age of the patients but not with the duration of the hospitalization. After the exclusion of IgM-anti-HAV, IgM-anti-CMV and IgM-anti-EBV or possible toxic effects, 2.6% of all patients remained as presumable non-A, non-B hepatitis infections. In this study HBV markers were not found in an hyperendemic pattern reported previously in psychiatric institutions.
 ...
PMID:Hepatitis markers in a psychiatric institution. 665 99

The number of patients treated with interferon (IFN) has increased markedly in Japan since 1992, when the Health and Welfare Ministry approved the use of IFN for treating chronic active hepatitis C. It is important to identify and treat depression, which is one of the psychiatric complications of IFN therapy and often leads to discontinuation of the therapy, in patients with chronic hepatitis C. In this study we prospectively investigated the incidence of depression during IFN therapy in patients with chronic active hepatitis C. The psychiatric status of 85 patients (53 men, 32 women; mean age 49.1 years) with chronic active hepatitis C who began receiving IFN at Showa University Hospital was assessed before and 2, 4, 12 and 24 weeks after the start of IFN therapy, using the major depressive episode diagnostic criteria listed in the DSM-III-R and the Hamilton Depression Scale HDS). All of the patients provided informed consent prior to participation in this study. IFN therapy was discontinued in 5 cases (5.9%) because of physical side effects and in 4 cases (4.7%) because of depression. Two, 11, 14, 25 and 16 patients were diagnosed as having major depressive episodes before and 2, 4, 12 and 24 weeks after the start of IFN therapy, respectively. The number of patients who were asymptomatic before the start of IFN therapy but were diagnosed as having a major depressive episode at least once during IFN therapy was 31 (31/83 = 37.3%). The mean HDS scores at 2, 4, 12 and 24 weeks (5.4, 6.0, 8.8 and 6.6) were significantly higher than that before the start of IFN therapy (3.0). The patients whose first diagnosed major depressive episodes occurred more than 4 weeks after the start of IFN therapy tended to be more severely depressed than those in whom it occurred less than 4 weeks after the start of IFN therapy. Compared to the 47 patients who completed 24 weeks of IFN therapy without experiencing depression, the 31 patients who were diagnosed as experiencing major depressive episodes during IFN therapy had significantly higher neuroticism scores determined using the Eysenck Personality Questionnaire, showed a more severely depressed mood and experienced more severe sleep disturbances before the start of IFN therapy. The latter group of patients also tended to have comorbid chronic physical disorders such as hypertension or diabetes mellitus and the histories of mental disorders before the IFN therapy; however these differences were not statistically significant. There were no differences between the two groups in patient age or sex, the severity of hepatitis before the IFN therapy, the type of IFN used in the therapy or the efficacy of IFN in the treatment of the hepatitis C. Our results indicate that the decision as to whether to treat chronic active hepatitis C with IFN should be made carefully and that early intervention and careful monitoring of depression are required during IFN therapy in the treatment of chronic active hepatitis C.
 ...
PMID:[Depression during interferon therapy in chronic hepatitis C patients--a prospective study]. 913 11

Hepatitis C virus (HCV) hepatitis and other diseases related to HCV, such as cryoglobulinemia, lymphoma and renal failure, impair health-related quality of life (HRQoL). In addition, HCV per se might directly influence HRQoL via colonization of microglia in the brain or, indirectly, via the effect of systemic inflammatory cytokines which, in turn, can trigger brain interleukin production. The treatment of HCV-related disorders with interferon (IFN) has an effect on HRQoL. Initially, IFN causes a transient deterioration of HRQoL, due to the induction of depression and other side effects of treatment. Subsequently, the subjects who obtain a sustained virologic response experience an improvement in HRQoL. Only rarely does interferon treatment causes permanent detrimental effects on HRQoL, due to residual psychiatric or neurologic side effects. Liver transplantation is the only treatment for end-stage HCV-related liver disease. HRQoL generally improves massively a few months after transplantation, except in the case of serious complications of the transplant procedure. Furthermore, high levels of anxiety and neuroticism pre-transplant are associated with lower HRQoL one year after transplant. Additionally, six months after transplant, patients with HCV who experience virologic recurrence show significantly greater depression, anxiety, phobic anxiety, and paranoid ideation than anti-HCV-negative patients. In conclusion, optimal care for the overall well-being of patients with HCV infection requires adequate knowledge of their neurological and psychological status.
 ...
PMID:Hepatitis C virus infection and health-related quality of life. 2265 20

Codonopsis lanceolata (Campanulaceae) is dicotyledonous herbaceous perennial plant, predominantly found in Central, East, and South Asia. This plant has been widely used in traditional medicine and is considered to have medicinal properties to treat diseases and symptoms such as bronchitis, coughs, spasm, psychoneurosis, cancer, obesity, hyperlipidemia, edema, hepatitis, colitis, and lung injury. C. lanceolata contains many biologically active compounds, including polyphenols, saponins, tannins, triterpene, alkaloids, and steroids, which contribute to its numerous pharmacological activities. Through systematic studies, the pharmacological actions of these compounds have been revealed. Therapeutic potentialities of C. lanceolata and its previously reported molecular mechanisms are described in this review.
 ...
PMID:Codonopsis lanceolata: A Review of Its Therapeutic Potentials. 2693 14